AIPM welcomes Sandoz as an independent member

December 15, 2023, Moscow. –  The Association of International Pharmaceutical Manufacturers (AIPM) announces the expansion of its membership. Following the results of the AIPM General Meeting, held on December 6, 2023, the pharmaceutical company Sandoz was admitted to the AIPM as a full member starting from January 1, 2024.

Previously, Sandoz had already been worked at the Association as a division of the Novartis Group of companies and within its membership provisions. Due to structural changes in both companies and Sandoz spin-off into the independent company, which was completed in October 2023, Sandoz made a decision to enter AIPM as an independent member.

Sandoz is one of the global leaders in generic and biosimilar medicines. The mission of our company is the pioneering access for patients to modern medicines all over the world. We are pleased to join the AIPM as a full member and believe in continuing our fruitful cooperation aimed at strengthening the healthcare system and providing patients with high-quality medicines," says Anna Bochkareva, Country Head of Sandoz Russia.

The company has been operated on the Russian market for 30 years, having a wide portfolio of medicines that are in a high demand for the healthcare system, covering about 20 therapeutic areas, including: oncology, cardiology, gastroenterology, rheumatology, infectious diseases, and others. Sandoz’s portfolio includes both prescription and over-the-counter products, specialized therapy, and biosimilars.

"The Association of International Pharmaceutical Manufacturers is the leading expert trade association targeting capabilities at expanding access to innovations and developing advanced regulatory standards in the pharmaceutical market and healthcare, as well as increasing the availability of effective and quality medicines for a wide range of patients in need. Since its foundation, AIPM has united companies representing all segments of the pharmaceutical market and contributed to both the early arrival of breakthrough pharmaceutical innovations and proper protection of intellectual property rights, as well as the development of competition, including the balanced price and assortment availability. The proficiency to offer optimal approaches and solutions to specific problems in the format of dialogue and social responsibility, the ability to find a rational balance, commitment to the development of basic ethical values, work for the benefit of Russian doctors and patients, as well as professional industry expertise are the distinctive features of the Association, which ensure our future common progress. We are open to any company who is ready to contribute to this work," said Katerina Pogodina, Vice-Chairman of the AIPM Board of Directors, Managing Director of Janssen, Pharmaceutical Products Division of Johnson & Johnson.

Reference:

The Association of International Pharmaceutical Manufacturers (AIPM) was established in 1994 and represents in the Russian Federation the leading international pharmaceutical companies - producers and developers of modern effective, safe and high-quality medicines. Today, AIPM unites 58 international companies that provide over 80% of the world’s pharmaceutical products and over 60% of medicines imported to the Russian Federation.

For additional information, please contact:

Elena Yankovskaya, PR & Communications Director, AIPM
+7 (495) 933 70 40, Elena.Yankovskaya@aipm.org